Aliskiren, the first in a new class of direct renin inhibitors for hypertension: present and future perspectives

Bibliography

• WOOD JM, MAIBAUM J, RAHUEL J et al.: Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem. Biophys. Res. Commun. (2003) 308(4):698-705.
   PubMed Web of Science ®Google Scholar
• KEARNEY PM, WHELTON M, REYNOLDS K, MUNTNER P, WHELTON PK, HE J: Global burden of hypertension: analysis of worldwide data. Lancet (2005) 365(9455):217-223.
   PubMed Web of Science ®Google Scholar
• WHO: World health report 2002; reducing risk, promoting healthy life. (Eds), World Health Organization, Geneva, Switzerland (2002).
   Google Scholar
• HOLLENBERG NK, FISHER ND, PRICE DA: Pathways for angiotensin II generation in intact human tissue: evidence from comparative pharmacological interruption of the renin system. Hypertension (1998) 32(3):387-392.
   PubMed Web of Science ®Google Scholar
• URATA H, KINOSHITA A, MISONO KS, BUMPUS FM, HUSAIN A: Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J. Biol. Chem. (1990) 265(36):22348-22357.
   PubMed Web of Science ®Google Scholar
• AZIZI M, WEBB R, NUSSBERGER J, HOLLENBERG NK: Renin inhibition with aliskiren: where are we now, and where are we going? J. Hypertens. (2006) 24(2):243-256.
   PubMed Web of Science ®Google Scholar
• STAESSEN JA, LI Y, RICHART T: Oral renin inhibitors. Lancet (2006) 368(9545):1449-1456.
   PubMed Web of Science ®Google Scholar
• LEFEVRE G, DUVAL M, PONCIN A: Direct micro-radioimmunoassay of the new renin inhibitor CGP 60536. J. Immunoassay (2000) 21(1):65-84.
   PubMed Web of Science ®Google Scholar
• ALLIKMETS K: Aliskiren (speedel). Curr. Opin. Investig. Drugs (2002) 3(10):1479-1482.
   PubMedGoogle Scholar
• BOHLENDER J, FUKAMIZU A, LIPPOLDT A et al.: High human renin hypertension in transgenic rats. Hypertension (1997) 29(1 Part 2):428-434.
   PubMed Web of Science ®Google Scholar
• WEBER MA, GILES TD: Inhibiting the renin-angiotensin system to prevent cardiovascular diseases: do we need a more comprehensive strategy? Rev. Cardiovasc. Med. (2006) 7(2):45-54.
   PubMed Web of Science ®Google Scholar
• MESSERLI FH, RE RN: Do we need yet another blocker of the renin-angiotensin system? J. Am. Coll. Cardiol. (2007) 49(11):1164-1165.
   PubMed Web of Science ®Google Scholar
• O'BRIEN E: Aliskiren: a renin inhibitor offering a new approach for the treatment of hypertension. Expert Opin. Investig. Drugs (2006) 15(10):1269-1277.
   PubMed Web of Science ®Google Scholar
• VAN TASSELL BW, MUNGER MA: Aliskiren for renin inhibition: a new class of antihypertensives. Ann. Pharmacother. (2007) 41(3):456-464.
   PubMed Web of Science ®Google Scholar
• NUSSBERGER J, WUERZNER G, JENSEN C, BRUNNER HR: Angiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP100): comparison with enalapril. Hypertension (2002) 39(1):E1-E8.
   PubMed Web of Science ®Google Scholar
• VAIDYANATHAN S, JIN Y, SCHILLER H, JENSEN C: Aliskiren, a novel oral renin inhibitor, has no interaction with cytochrome P450 isoenzymes in vitro. Basic Res. Pharmacol. Toxicol. (2005) 97(Suppl. 1):239.
   Google Scholar
• VAIDYANATHAN S, JERMANY J, YEH C, BIZOT MN, CAMISASCA R: Aliskiren, a novel orally effective renin inhibitor, exhibits similar pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects. Br. J. Clin. Pharmacol. (2006) 62(6):690-698.
   PubMed Web of Science ®Google Scholar
• DIETERLE W, CORYNEN S, MANN J: Effect of the oral renin inhibitor aliskiren on the pharmacokinetics and pharmacodynamics of a single dose of warfarin in healthy subjects. Br. J. Clin. Pharmacol. (2004) 58(4):433-436.
   PubMed Web of Science ®Google Scholar
• DIETERLE W, CORYNEN S, VAIDYANATHAN S, MANN J: Pharmacokinetic interactions of the oral renin inhibitor aliskiren with lovastatin, atenolol, celecoxib and cimetidine. Int. J. Clin. Pharmacol. Ther. (2005) 43(11):527-535.
   PubMed Web of Science ®Google Scholar
• VAIDYANATHAN S, VALENCIA J, KEMP C et al.: Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers. Int. J. Clin. Pract. (2006) 60(11):1343-1356.
   PubMed Web of Science ®Google Scholar
• GRADMAN AH, SCHMIEDER RE, LINS RL, NUSSBERGER J, CHIANG Y, BEDIGIAN MP: Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation (2005) 111(8):1012-1018.
   PubMed Web of Science ®Google Scholar
• OH BH, MITCHELL J, HERRON JR, CHUNG J, KHAN M, KEEFE DL: Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-h blood pressure control in patients with hypertension. J. Am. Coll. Cardiol. (2007) 49(11):1157-1163.
   PubMed Web of Science ®Google Scholar
• DAHLÖF B, ANDERSON DR, ARORA V, BUSH C, KEEFE DL: Aliskiren, a direct renin inhibitor, provides antihypertensive efficacy and excellent tolerability independent of age or gender in patients with hypertension. J. Clin. Hypertens. (2007) 9(Suppl. A):376 (A157).
   Google Scholar
• OPARIL S, YARROWS SA, PATEL S, FANG H, ZHANG J, SATLIN A: Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet (2007) 370:221-229.
   PubMed Web of Science ®Google Scholar
• ANDERSEN K, WEINBERGER MH, EGAN B et al.: Aliskiren-based therapy lowers blood pressure more effectively than ramipril-based therapy in patients with hypertension: a 6-month, randomized, double blind trial. J. Am. Coll. Cardiol. (2007) 49(Suppl. 1):A371.
   Google Scholar
• STRASSER RH, PUIG JG, FARSANG C, CROKET M, LI J, VAN INGEN H: A comparison of the tolerability of the direct renin inhibitor aliskiren and lisinopril in patients with severe hypertension. J. Hum. Hypertens. (2007).
   PubMedGoogle Scholar
• SCHMIEDER RE, PHILIPP T, GUEREDIAGA J et al.: Aliskiren-based therapy lowers blood pressure more efficiently than hydrochlorothiazide-based therapy in patients with hypertension. J. Clin. Hypertens. (2007) 9(Suppl. A):A182 (P-436).
   Google Scholar
• MANCIA G, DE BACKER G, DOMINICZAK A et al.: 2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European society of hypertension (ESH) and of the European society of cardiology (ESC). Eur. Heart J. (2007) 28(12):1462-1536.
   PubMed Web of Science ®Google Scholar
• VILLAMIL A, CHRYSANT SG, CALHOUN D et al.: Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J. Hypertens. (2007) 25(1):217-226.
   PubMed Web of Science ®Google Scholar
• JORDAN J, ENGELI S, BOYE SW, LE BRETON S, KEEFE DL: Direct renin inhibition with aliskiren in obese patients with arterial hypertension. Hypertension (2007) 49(5):1047-1055.
   PubMed Web of Science ®Google Scholar
• URESIN Y, TAYLOR A, KILO C et al.: Aliskiren, a novel renin inhibitor, has greater BP lowering than ramipril and additional BP lowering when combined with ramipril in patients with diabetes and hypertension. J. Clin. Hypertens. (2006) 24(Suppl. 4):S82 (P-269).
   Google Scholar
• MUNGER MA, DRUMMOND W, ESSOP MR, MABOUDIAN M, KHAN M, KEEFE DL: Aliskiren as add-on to amlodipine provides significant additional blood pressure lowering without increased oedema associated with doubling the amlodipine dose. Eur. Heart J. (2006) 27(Suppl.):117 (P-784).
   PubMedGoogle Scholar
• WEIR MR, BUSH C, ANDERSON DR et al.: Antihypertensive efficacy, safety, and tolerability of the oral direct renin inhibitor Aliskiren in patients with hypertension: a pooled analysis. JASH (2007) 1(4):264-277.
   Google Scholar
• PILZ B, SHAGDARSUREN E, WELLNER M et al.: Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension (2005) 46(3):569-576.
   PubMed Web of Science ®Google Scholar
• SEALEY JE, LARAGH JH: Aliskiren, the first renin inhibitor for treating hypertension: reactive renin secretion may limit its effectiveness. Am. J. Hypertens. (2007) 20(5):587-597.
   PubMed Web of Science ®Google Scholar
• TAYLOR AA, ANDERSON DR, ARORA V, SATLIN A, PRESCOTT MF: Renin system suppression with the oral direct renin inhibitor aliskiren administered alone or in combination: a pooled analysis of 1093 patients with hypertension. J. Am. Coll. Cardiol. (2007) 49(9 Suppl. A):A370 (P-1014-1170).
   Google Scholar